Fig. 4: PUMA is required for the antitumor effects of BRD9 inhibition.
A Nude mice were injected s.c. with 5 × 106 WT or PUMA-KO GIST-882 cells. After 7 days, mice were treated with 10 mg/kg GSK602 or the vehicle control for 10 consecutive days. Tumor volume at indicated time points after treatment was calculated and plotted with p values, n = 6 in each group. B Mice weight after treatment. C Mice with WT GIST-882 xenograft tumors were treated with 10 mg/kg GSK602 or the vehicle as in (A) for 4 consecutive days. The level of PUMA in three randomly selected tumors were analyzed by Western blotting. D Paraffin-embedded sections of WT or PUMA-KO tumor tissues from mice treated as in (C) were analyzed by TUNEL staining. Left, representative TUNEL staining pictures; Right, TUNEL-positive cells were counted and plotted, Scale bar: 25 μm. E Tissue sections from (D) were analyzed by active caspase 3 staining. Left, representative staining pictures; Right, active caspase 3-positive cells were counted and plotted, Scale bar: 25 μm. Results were expressed as means ± SD of three independent experiments. *P < 0.05.
